TTF-1-positive Metastatic Endometrioid Carcinoma: A Case Report and Review of Literature of a Potential Diagnostic Pitfall.
Aged
Amino Acid Substitution
Class I Phosphatidylinositol 3-Kinases
/ genetics
DNA-Binding Proteins
/ biosynthesis
Endometrial Neoplasms
/ diagnosis
Female
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ diagnosis
Mutation, Missense
Neoplasm Metastasis
Neoplasm Proteins
/ genetics
Transcription Factors
/ biosynthesis
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
5
8
2017
medline:
24
11
2020
entrez:
5
8
2017
Statut:
ppublish
Résumé
A 75-year-old female patient, nonsmoker was addressed to our institution for a fracture of C5 vertebra with spinal cord compression by a tumor mass invading surrounding soft tissue. She had a previous history of breast ductal carcinoma and endometrioid carcinoma. Biopsy of the tumor mass showed a TTF-1-positive carcinoma. Molecular study showed a E545K mutation of PIK3CA. Lung imaging showed multiple nodules evocative of metastasis rather than a primitive tumor. Reviewing of slides of endometrioid carcinoma showed areas positive for TTF1, and the same E545K mutation was found in endometrial tumor. The final diagnosis was endometrioid metastatic carcinoma with aberrant TTF-1 expression. A subset of endometrial neoplasm expresses TTF-1, this situation might be confusing especially in case of metastatic disease.
Identifiants
pubmed: 28777147
doi: 10.1097/PAI.0000000000000539
pii: 00129039-202001000-00014
doi:
Substances chimiques
DNA-Binding Proteins
0
Neoplasm Proteins
0
TTF1 protein, human
0
Transcription Factors
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e6-e9Références
Forest F, Casteillo F, Manet R, et al. A 48-year-old male with a pituitary tumor: correspondence. Brain Pathol. 2016;26:130–131.
Sullivan PS, Maresh EL, Seligson DB, et al. Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Mod Pathol. 2012;25:1140–1148.
Niu H-L, Pasha TL, Pawel BR, et al. Thyroid transcription factor-1 expression in normal gynecologic tissues and its potential significance. Int J Gynecol Pathol. 2009;28:301–307.
Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001;93:330–336.
Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003;442:271–277.
Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:1759–1763.
Zhang PJ, Gao HG, Pasha TL, et al. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10–18.
Fujiwara S, Nawa A, Nakanishi T, et al. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. Hum Pathol. 2010;41:560–565.
Han C-P, Kok L-F, Lee M-Y, et al. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Arch Gynecol Obstet. 2010;281:317–323.
Ervine A, Leung S, Gilks CB, et al. Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. Histopathology. 2014;64:840–846.
Kim M-Y, Go H, Koh J, et al. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin. Histopathology. 2014;65:195–206.
Iwamoto M, Nakatani Y, Fugo K, et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol. 2015;46:957–962.
Ferrandina G, Palluzzi E, Fanfani F, et al. Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. World J Surg Oncol. 2016;14:300.
McFarland M, Quick CM, McCluggage WG. Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. Histopathology. 2016;68:1013–1020.
Ye J, Hameed O, Findeis-Hosey J, et al. Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech Histochem. 2012;87:30–34.
El-Maqsoud NMRA, Tawfiek ER, Abdelmeged A, et al. The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas. Tumour Biol. 2016;37:3123–3134.
Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485–490.
Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011;19:313–317.
Al-Maghrabi JA, Butt NS, Anfinan N, et al. Infrequent immunohistochemical expression of napsin a in endometrial carcinomas. Appl Immunohistochem Mol Morphol. 2016. DOI: 10.1097/PAI.0000000000000350.
doi: 10.1097/pai.0000000000000350
Zhang Y, Qu X, Qu PP. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma. J BUON. 2016;21:1491–1495.
Marchiò C, De Filippo MR, Ng CKY, et al. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecol Oncol. 2015;137:321–328.
Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13:e1002201.
Huang M, Djordjevic B, Yates MS, et al. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013;119:3027–3033.
Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–1426.